Ser1420

Site Information
EVKARsQsGtLDGEs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454015

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 12 , 14 ) , mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , mutation of modification site ( 12 ) , peptide sequencing ( 1 ) , phospho-antibody ( 1 , 13 ) , western blotting ( 1 , 13 )
Disease tissue studied:	breast cancer ( 4 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 4 ) , ovarian cancer ( 4 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 1 ) , 293 (epithelial) [TSC1 (human)] ( 14 ) , 293 (epithelial) [TSC2 (human)] ( 14 ) , 293 (epithelial) ( 10 , 12 ) , 293E (epithelial) ( 13 ) , breast ( 2 , 4 ) , HeLa (cervical) ( 6 , 7 , 9 , 11 ) , Jurkat (T lymphocyte) ( 5 , 8 ) , K562 (erythroid) ( 6 ) , ovary ( 4 )

Upstream Regulation
Treatments:	phorbol_ester ( 13 , 14 )

References
1	Jacobs BL, et al. (2017) Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling. J Biol Chem 292, 6987-6997 28289099 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
8	Zhou J (2011) CST Curation Set: 12496; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Dubois F, et al. (2009) Differential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signaling. Mol Cell Proteomics 8, 2487-99 19648646 Curated Info
10	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
11	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
12	Nellist M, et al. (2005) Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Biochem Biophys Res Commun 333, 818-26 15963462 Curated Info
13	Ballif BA, et al. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A 102, 667-72 15647351 Curated Info
14	Roux PP, et al. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101, 13489-94 15342917 Curated Info